Chilean scientist Tomas Egaña introduced a research yesterday, creating the first version of the photosynthetic skin that produces and releases oxygen and is capable of regenerating human tissue.
During a presentation at the Catholic University of Chile, Egaña, PhD in Human Biology and Pharmacology, explained that after eight years of analysis and testing with animals (rats, pigs and fish), the first clinical study was carried out at El Salvador Santiago Hospital, with 20 patients suffered a trauma.
"This step, which lasts for six months, is small but very important for demonstrating the safety of technology. If we can manage it, we can apply it to other types of patients and diseases, such as organ transplants and oncologists," Egaña said in her statements .
This research, which took place at the Catholic University of Chile, developed the first method for skin transplantation by implanting genetically modified microalgae for oxygen production and regeneration.
"90% of the cells in our body are not human, and the human body is a real ecosystem where micro-organisms and human cells coexist," said Egaña during the presentation, which is what happens in the body if we implant microscopes that produce photosynthesis.
Photosynthesis is a process that plants do when they break water molecules with light energy and release the oxygen that all living creatures on the planet consume, said a Chilean scientist.
"The big question is what could be achieved if people were able to reproduce this process in a therapeutic context because there are many diseases caused by oxygen deficiency, such as bleeding, heart attacks or large wounds that do not heal," Egaña added.
The first series of investigations focuses on the possible use of this technique in wounds to oxidize creams, bandages or sutures containing micro-organisms that perform photosynthesis.
While the second line examines the use of this technology in organ transplants to ensure that the organs live longer than the body and in oncological therapies to achieve greater elimination of cancer cells.
At the beginning of his research at the University of Lübeck, Germany, where he obtained the Egaña Doctorate, he successfully developed a test in which he sprayed a fish embryo, some of the micros and successfully merged "without kelp, killing an embryo and killing the kelp without an embryo."
Avoid rejection. As pointed out by researcher Tomas Egaña, the key to this first clinical trial will be to avoid refusing patients to these transplants.
Remove the implant. In the event that 20 patients have successfully received skin transplantation, it is thought that when the skin is regenerated, the implant is removed by the same body or removed.
Implementation The next six months will be necessary to determine the possible realization of this technique in the future of medicine.